Business
Mannatech develops and sells nutritional supplements, skin-care products and wellness products through a direct-selling network.
Mannatech's wellness revenue declined again and losses and cash burn deepened, while the filing's going-concern warning makes liquidity more important than its global distributor footprint.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 8.3%Watch
- Profitability — The company moved from net income of $2.49M to a net loss of $15.213MWatch
- Cash flow — Free cash flow turned negative at an outflow of $4.316M from $1.964MWatch
- Margins — Operating margin contracted 160 bps to -0.39%Watch
- Accounting — Going-concern warning after continued contractionWatch
- Insiders — 3 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as MANNATECH INC reports it. History and quarterly detail are in the app.
- Product$106.0M
- Product and Service, Other$1.6M
- Associate Service Fees$400K
- Associate Fees$400K
Leadership changes
From MANNATECH INC's own filings, the day they're filed.
- Yasir Haider · Chief Financial Officer · appointmenteff. 2026-06-03
- Yasir Haider · CFO · appointmenteff. 2026-03-20
- James Clavijo · Chief Financial Officer · appointmenteff. 2024-07-01
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about MANNATECH INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.